(Q35023542)

5 August 2017

1 reference

title

Towards immunotherapy for chronic hepatitis B virus infections (English)

1 reference

5 August 2017

1 reference

1 reference

1 reference

1 reference

Michel ML

1

1 reference

PubMed ID

12477434

5 August 2017

language of work or name

English

0 references

publication date

1 December 2002

1 reference

5 August 2017

1 reference

5 August 2017

20 Suppl 4

1 reference

5 August 2017

A83-8

1 reference

Hepatitis B virus infection

5 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900393-6

7 January 2021

The treatment of chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900393-6

7 January 2021

Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900393-6

7 January 2021

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900393-6

7 January 2021

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900393-6

7 January 2021

Hepatitis B virus immunopathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900393-6

7 January 2021

Viral Clearance Without Destruction of Infected Cells During Acute HBV Infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900393-6

7 January 2021

Cytokine-induced viral purging--role in viral pathogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900393-6

7 January 2021

The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900393-6

7 January 2021

Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900393-6

7 January 2021

Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900393-6

7 January 2021

Specific vaccine therapy in chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900393-6

7 January 2021

Efficacy and limitations of a specific immunotherapy in chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900393-6

7 January 2021

Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900393-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900393-6

1 reference

7 January 2021

DNA vaccines for prophylactic or therapeutic immunization against hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900393-6

7 January 2021

Human hepatitis B vaccine from recombinant yeast

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900393-6

7 January 2021

Synthesis in animal cells of hepatitis B surface antigen particles carrying a receptor for polymerized human serum albumin

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900393-6

7 January 2021

Human T cell response to the surface antigen of hepatitis B virus (HBsAg). Endosomal and nonendosomal processing pathways are accessible to both endogenous and exogenous antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900393-6

7 January 2021

Hepatitis B virus small surface antigen particles are processed in a novel endosomal pathway for major histocompatibility complex class I-restricted epitope presentation

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900393-6

7 January 2021

Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900393-6

7 January 2021

Placebo-controlled trial of vaccination with hepatitis B virus surface antigen in hepatitis B virus transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900393-6

7 January 2021

Induction of anti-hepatitis B surface antigen (HBsAg) antibodies in HBsAg producing transgenic mice: a possible way of circumventing "nonresponse" to HBsAg.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900393-6

7 January 2021

Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900393-6

7 January 2021

Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900393-6

7 January 2021

Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900393-6

7 January 2021

CpG oligodeoxynucleotides with hepatitis B surface antigen (HBsAg) for vaccination in HBsAg-transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900393-6

7 January 2021

CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900393-6

7 January 2021

Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900393-6

7 January 2021

A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900393-6

7 January 2021

DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900393-6

7 January 2021

DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900393-6

7 January 2021

DNA-mediated immunization to hepatitis B surface antigen: longevity of primary response and effect of boost.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900393-6

7 January 2021

Multiepitopic HLA-A*0201-restricted immune response against hepatitis B surface antigen after DNA-based immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900393-6

7 January 2021

DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900393-6

7 January 2021

Protective and therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900393-6

7 January 2021

Evaluation of new approaches to prophylactic and therapeutic vaccinations against hepatitis B viruses in the woodchuck model

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900393-6

7 January 2021

DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900393-6

7 January 2021

In vivo induction of specific cytotoxic T lymphocytes in mice and rhesus macaques immunized with DNA vector encoding an HIV epitope fused with hepatitis B surface antigen.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900393-6

7 January 2021

Successful nucleic acid based immunization of newborn chimpanzees against hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900393-6

7 January 2021

DNA prime/canarypox boost-based immunotherapy of chronic hepatitis B virus infection in a chimpanzee

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900393-6

7 January 2021

Genetic immunization of chimpanzees chronically infected with the hepatitis B virus, using a recombinant retroviral vector encoding the hepatitis B virus core antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900393-6

7 January 2021

10.1016/S0264-410X(02)00393-6

Identifiers

DOI

1 reference

5 August 2017

1 reference

PubMed ID

12477434